GH RSI Chart
Last 7 days
13.4%
Last 30 days
54.7%
Last 90 days
13.1%
Trailing 12 Months
-14.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 603.7M | 0 | 0 | 0 |
2023 | 482.2M | 510.2M | 535.8M | 563.9M |
2022 | 391.1M | 408.1M | 430.8M | 449.5M |
2021 | 297.9M | 323.7M | 343.9M | 373.7M |
2020 | 245.2M | 257.6M | 271.3M | 286.7M |
2019 | 110.6M | 145.2M | 184.4M | 214.4M |
2018 | 60.0M | 70.2M | 80.4M | 90.6M |
2017 | 0 | 0 | 37.5M | 49.8M |
2016 | 0 | 0 | 0 | 25.2M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 04, 2024 | joyce meghan v. | acquired | - | - | 66.00 | - |
May 03, 2024 | eltoukhy helmy | acquired | 836,000 | 4.18 | 200,000 | co-chief executive officer |
May 02, 2024 | talasaz amirali | acquired | 1,186,410 | 4.18 | 283,830 | co-chief executive officer |
Apr 30, 2024 | krognes steve e. | acquired | - | - | 154 | - |
Apr 15, 2024 | tariq musa | acquired | - | - | 249 | - |
Apr 15, 2024 | saia john g. | sold (taxes) | -64,981 | 17.06 | -3,809 | chief legal officer |
Apr 15, 2024 | saia john g. | acquired | - | - | 7,569 | chief legal officer |
Apr 15, 2024 | potter myrtle s | acquired | - | - | 68.00 | - |
Apr 04, 2024 | joyce meghan v. | acquired | - | - | 67.00 | - |
Apr 01, 2024 | chudova darya | acquired | - | - | 1,340 | chief technology officer |
Which funds bought or sold GH recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | COMERICA BANK | reduced | -83.51 | -229,618 | 33,023 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | added | 15.06 | -602,667 | 4,318,110 | -% |
May 16, 2024 | COMERICA BANK | sold off | -100 | -700 | - | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.65 | -823,232 | 2,373,560 | -% |
May 16, 2024 | Colony Group, LLC | new | - | 359,000 | 359,000 | -% |
May 16, 2024 | Adalta Capital Management LLC | added | 15.56 | -197,235 | 1,465,200 | 0.81% |
May 16, 2024 | JANE STREET GROUP, LLC | added | 64.12 | 1,059,040 | 2,853,270 | -% |
May 15, 2024 | MARSHALL WACE, LLP | new | - | 2,473,080 | 2,473,080 | -% |
May 15, 2024 | Temasek Holdings (Private) Ltd | added | 11.92 | -14,547,700 | 84,813,500 | 0.47% |
May 15, 2024 | Granahan Investment Management, LLC | new | - | 4,093,690 | 4,093,690 | 0.14% |
Unveiling Guardant Health Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Guardant Health Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
DHR | 196.9B | 23.7B | 44.73 | 8.29 | ||||
A | 45.2B | 6.7B | 36.57 | 6.71 | ||||
IDXX | 44.9B | 3.7B | 51.83 | 12.06 | ||||
DGX | 16.0B | 9.3B | 18.95 | 1.73 | ||||
NTRA | 13.1B | 1.2B | -35.76 | 10.81 | ||||
MEDP | 12.2B | 2.0B | 38.94 | 6.2 | ||||
CRL | 11.4B | 4.1B | 26.02 | 2.78 | ||||
EXAS | 9.3B | 2.5B | -38.69 | 3.67 | ||||
MID-CAP | ||||||||
GH | 3.1B | 603.7M | -6.73 | 5.14 | ||||
NEOG | 2.9B | 929.2M | 1.9K | 3.16 | ||||
SMALL-CAP | ||||||||
CDNA | 808.3M | 275.1M | -4.41 | 2.94 | ||||
ACRS | 84.8M | 31.1M | -1.1 | 2.73 | ||||
AWH | 33.0M | 9.2M | -2.24 | 3.6 | ||||
APDN | 2.5M | 5.5M | -0.2 | 0.45 | ||||
BIOC | 183.8K | 25.9M | -0.01 | 0.01 |
Guardant Health Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 8.7% | 168,491,000 | 155,054,000 | 143,030,000 | 137,150,000 | 128,714,000 | 126,891,000 | 117,404,000 | 109,144,000 | 96,099,000 | 108,108,000 | 94,779,000 | 92,101,000 | 78,665,000 | 78,316,000 | 74,569,000 | 66,335,000 | 67,510,000 | 62,897,000 | 60,848,000 | 53,975,000 | 36,655,000 |
Costs and Expenses | -23.9% | 268,174,000 | 352,565,000 | 256,573,000 | 256,766,000 | 262,769,000 | 273,010,000 | 262,004,000 | 239,465,000 | 219,437,000 | 206,316,000 | 202,067,000 | 189,743,000 | 186,528,000 | 169,482,000 | 148,821,000 | 120,955,000 | 102,422,000 | 88,859,000 | 78,325,000 | 69,243,000 | 60,319,000 |
S&GA Expenses | 1.6% | 80,425,000 | 79,127,000 | 68,934,000 | 71,043,000 | 76,123,000 | 81,423,000 | 80,370,000 | 73,603,000 | 64,432,000 | 59,599,000 | 50,228,000 | 47,716,000 | 34,338,000 | 31,288,000 | 25,095,000 | 25,015,000 | 25,115,000 | 22,287,000 | 18,802,000 | 19,439,000 | 17,807,000 |
R&D Expenses | -6.7% | 83,802,000 | 89,856,000 | 93,851,000 | 90,359,000 | 93,128,000 | 106,578,000 | 100,017,000 | 85,455,000 | 81,757,000 | 73,021,000 | 70,968,000 | 63,724,000 | 55,508,000 | 40,282,000 | 36,245,000 | 36,319,000 | 37,016,000 | 25,875,000 | 24,569,000 | 19,532,000 | 16,316,000 |
EBITDA Margin | 10.7% | -0.69 | -0.77 | -0.72 | -0.91 | -1.29 | -1.37 | -1.28 | -1.23 | -0.95 | -0.96 | -1.10 | -1.06 | - | - | - | - | - | - | - | - | - |
Interest Expenses | 0% | 645,000 | 645,000 | 644,000 | 645,000 | 644,000 | 644,000 | 644,000 | 645,000 | 644,000 | 643,000 | 644,000 | 644,000 | 646,000 | 4,736,000 | 8,000 | 10,000 | 12,000 | 321,000 | 280,000 | 287,000 | 293,000 |
Income Taxes | 174.9% | 405,000 | -541,000 | 490,000 | 496,000 | 240,000 | 602,000 | 115,000 | 446,000 | -24,000 | 11,000 | 96,000 | 83,000 | 110,000 | 263,000 | 68,000 | 34,000 | 14,000 | -489,000 | -202,000 | -1,207,000 | 26,000 |
Earnings Before Taxes | 38.9% | -114,580,000 | -187,584,000 | -85,612,000 | -72,275,000 | -133,293,000 | -139,332,000 | -161,879,000 | -228,986,000 | -123,252,000 | -72,300,000 | -107,430,000 | -97,492,000 | -107,248,000 | -92,782,000 | -71,602,000 | -49,705,000 | -31,815,000 | -22,599,000 | -13,292,000 | -12,507,000 | -21,325,000 |
EBT Margin | 10.2% | -0.76 | -0.85 | -0.80 | -0.99 | -1.38 | -1.45 | -1.36 | -1.30 | -1.02 | -1.03 | -1.18 | -1.14 | - | - | - | - | - | - | - | - | - |
Net Income | 38.5% | -114,985,000 | -187,043,000 | -86,102,000 | -72,771,000 | -133,533,000 | -139,934,000 | -161,994,000 | -229,432,000 | -123,228,000 | -72,311,000 | -107,526,000 | -97,575,000 | -107,358,000 | -93,045,000 | -71,670,000 | -49,739,000 | -31,829,000 | -22,110,000 | -13,090,000 | -11,300,000 | -21,351,000 |
Net Income Margin | 10.2% | -0.76 | -0.85 | -0.81 | -1.00 | -1.38 | -1.46 | -1.36 | -1.30 | -1.02 | -1.03 | -1.18 | -1.14 | - | - | - | - | - | - | - | - | - |
Free Cashflow | 55.1% | -37,218,000 | -82,805,000 | -80,163,000 | -100,528,000 | -81,965,000 | -100,750,000 | -99,886,000 | -134,969,000 | -51,319,000 | -101,613,000 | -75,294,000 | -81,268,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -4.6% | 1,705 | 1,786 | 1,797 | 1,840 | 1,512 | 1,610 | 1,702 | 1,854 | 2,130 | 2,204 | 2,226 | 2,292 | 2,347 | 2,272 | 1,262 | 1,278 | 948 | 963 | 948 | 940 | 579 |
Current Assets | -2.9% | 1,309 | 1,347 | 1,347 | 1,398 | 1,104 | 1,192 | 1,131 | 1,037 | 1,113 | 1,114 | 1,593 | 1,891 | 2,033 | 1,888 | 1,087 | 1,010 | 607 | 597 | 583 | 604 | 512 |
Cash Equivalents | -0.4% | 1,129 | 1,134 | 457 | 271 | 224 | 142 | 158 | 215 | 574 | 492 | 832 | 939 | 869 | 833 | 143 | 165 | 152 | 143 | 147 | 175 | 154 |
Inventory | 1.7% | 63.00 | 62.00 | 77.00 | 61.00 | 46.00 | 52.00 | 63.00 | 60.00 | 37.00 | 31.00 | 25.00 | 26.00 | 29.00 | 23.00 | 28.00 | 20.00 | 25.00 | 15.00 | 15.00 | 14.00 | 10.00 |
Net PPE | -4.6% | 138 | 145 | 148 | 156 | 163 | 168 | 168 | 163 | 151 | 124 | 106 | 90.00 | 72.00 | 63.00 | 62.00 | 57.00 | 47.00 | 44.00 | 41.00 | 35.00 | 31.00 |
Goodwill | 0% | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | - | - |
Liabilities | 0.5% | 1,636 | 1,628 | 1,569 | 1,547 | 1,556 | 1,550 | 1,535 | 1,535 | 1,597 | 1,559 | 1,457 | 1,444 | 1,440 | 916 | 114 | 113 | 118 | 115 | 86.00 | 78.00 | 65.00 |
Current Liabilities | 6.8% | 220 | 206 | 227 | 201 | 204 | 193 | 175 | 168 | 229 | 195 | 102 | 97.00 | 96.00 | 67.00 | 72.00 | 70.00 | 82.00 | 73.00 | 68.00 | 57.00 | 48.00 |
Long Term Debt | 0.1% | 1,141 | 1,140 | 1,139 | 1,139 | 1,138 | 1,137 | 1,137 | 1,136 | 1,135 | 1,135 | 1,134 | 1,134 | 1,133 | 806 | - | - | - | - | - | - | - |
LT Debt, Non Current | -100.0% | - | 1,140 | 1,139 | 1,139 | 1,138 | 1,137 | 1,137 | 1,136 | 1,135 | 1,135 | 1,134 | 1,134 | 1,133 | 806 | - | - | - | - | - | - | - |
Shareholder's Equity | -57.0% | 68.00 | 159 | 228 | 293 | -44.55 | 60.00 | 167 | 319 | 533 | 645 | 709 | 788 | 847 | 1,298 | 1,092 | 1,115 | 785 | 798 | 815 | 815 | 468 |
Retained Earnings | -5.4% | -2,256 | -2,141 | -1,954 | -1,868 | -1,795 | -1,662 | -1,522 | -1,360 | -1,131 | -1,007 | -916 | -809 | -711 | -606 | -512 | -435 | -380 | -352 | -327 | -314 | -303 |
Additional Paid-In Capital | 1.1% | 2,330 | 2,304 | 2,189 | 2,170 | 1,764 | 1,742 | 1,716 | 1,704 | 1,682 | 1,658 | 1,627 | 1,597 | 1,558 | 1,902 | 1,601 | 1,544 | 1,158 | 1,150 | 1,142 | 1,129 | 771 |
Shares Outstanding | 0.1% | 122 | 122 | 118 | 118 | 103 | 103 | 102 | 102 | 102 | 101 | 101 | 101 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 4,100 | - | - | - | 4,000 | - | - | - | 12,100 | - | - | - | 7,600 | - | - | - | 3,400 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 61.5% | -30,284 | -78,728 | -77,791 | -94,015 | -74,441 | -90,749 | -78,160 | -111,935 | -28,619 | -76,988 | -53,145 | -62,593 | -16,291 | -59,223 | -8,057 | -23,365 | -13,282 | -30,342 | 1,347 | -13,836 | -4,303 |
Share Based Compensation | 11.2% | 27,041 | 24,320 | 21,819 | 22,354 | 22,266 | 23,703 | 20,639 | 25,544 | 24,799 | 26,857 | 35,016 | 34,507 | 55,069 | 56,762 | 55,198 | 25,815 | 6,338 | 5,072 | 5,484 | 3,216 | 3,182 |
Cashflow From Investing | -95.8% | 28,066 | 663,454 | 260,699 | -241,127 | 157,224 | 70,627 | 41,274 | -72,893 | 110,808 | -266,697 | -47,394 | 127,066 | 123,870 | -297,685 | -14,656 | -325,549 | 20,804 | 23,358 | -35,730 | -320,527 | 15,329 |
Cashflow From Financing | -101.2% | -1,074 | 90,568 | 3,807 | 383,854 | -854 | 2,318 | -19,312 | -172,087 | -12.00 | 3,780 | -5,560 | 4,909 | -69,953 | 1,046,724 | 797 | 361,320 | 1,466 | 3,077 | 6,871 | 355,068 | 2,288 |
Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue: | ||
Precision oncology testing | $ 156,229 | $ 113,393 |
Development services and other | 12,262 | 15,321 |
Total revenue | 168,491 | 128,714 |
Costs and operating expenses: | ||
Cost of precision oncology testing | 59,306 | 45,106 |
Cost of development services and other | 5,990 | 7,967 |
Research and development expense | 83,802 | 93,128 |
Sales and marketing expense | 80,425 | 76,123 |
General and administrative expense | 38,651 | 40,445 |
Total costs and operating expenses | 268,174 | 262,769 |
Loss from operations | (99,683) | (134,055) |
Interest income | 14,868 | 3,060 |
Interest expense | (645) | (644) |
Other income (expense), net | (29,120) | (1,654) |
Loss before provision for income taxes | (114,580) | (133,293) |
Provision for income taxes | 405 | 240 |
Net loss | $ (114,985) | $ (133,533) |
Net loss per share, basic (in usd per share) | $ (0.94) | $ (1.30) |
Net loss per share, diluted (in usd per share) | $ (0.94) | $ (1.30) |
Weighted-average shares used in computing net loss per share, basic (in shares) | 121,712 | 102,663 |
Weighted-average shares used in computing net loss per share, diluted (in shares) | 121,712 | 102,663 |
Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash, cash equivalents and restricted cash | $ 1,129,257 | $ 1,133,687 |
Cash, cash equivalents and restricted cash | 1,133,537 | |
Short-term marketable debt securities | 0 | 35,097 |
Accounts receivable, net | 84,562 | 88,783 |
Inventory, net | 62,991 | 61,948 |
Prepaid expenses and other current assets, net | 31,736 | 27,741 |
Total current assets | 1,308,546 | 1,347,106 |
Property and equipment, net | 138,387 | 145,096 |
Right-of-use assets, net | 151,881 | 157,616 |
Intangible assets, net | 8,294 | 8,979 |
Goodwill | 3,290 | 3,290 |
Other assets, net | 94,200 | 124,334 |
Total Assets | 1,704,598 | 1,786,421 |
Current liabilities: | ||
Accounts payable | 37,603 | 51,741 |
Accrued compensation | 92,639 | 72,736 |
Accrued expenses | 67,211 | 63,475 |
Deferred revenue | 22,556 | 17,965 |
Total current liabilities | 220,009 | 205,917 |
Convertible senior notes, net | 1,140,611 | 1,139,966 |
Long-term operating lease liabilities | 178,907 | 185,848 |
Other long-term liabilities | 96,786 | 96,006 |
Total Liabilities | 1,636,313 | 1,627,737 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of March 31, 2024, and December 31, 2023; 121,787,297 and 121,629,861 shares issued and outstanding as of March 31, 2024, and December 31, 2023, respectively | 1 | 1 |
Additional paid-in capital | 2,329,930 | 2,304,220 |
Accumulated other comprehensive loss | (4,799) | (3,675) |
Accumulated deficit | (2,256,847) | (2,141,862) |
Total Stockholders’ Equity | 68,285 | 158,684 |
Total Liabilities and Stockholders’ Equity | $ 1,704,598 | $ 1,786,421 |